– USA, MA – Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that current COO, Bryan Stuart will join the Board of Directors as president and CEO, succeeding Dr. Robert Gould who will be retiring as of March 31, 2021, but will remain on the Board of Directors as an advisor.
Additionally, Board Chair, Mark Levin will assume the role of executive chair effective upon Dr. Gould’s retirement.
“On behalf of the entire Board, I want to thank Robert for his leadership and dedication to Fulcrum,” said Mark Levin. “Robert joined us as CEO in 2016 and was instrumental in ensuring Fulcrum’s successful launch. His decades of experience and steadfast dedication have positioned Fulcrum to make significant and rapid progress in its goal to create therapies for genetically defined rare diseases. We wish Robert the best in his retirement and are grateful that he will continue to be a member of our board and serve as an advisor.”
“Bryan is the ideal candidate to lead Fulcrum through its next critical stage of growth,” continued Mr. Levin. “He is a trusted and strategic leader and a natural successor to Robert. Bryan brings over 20 years of industry experience, predominantly in the rare disease space. With his proven track record of helping to successfully advance numerous rare disease programs from the clinic to commercialization, I’m confident he will bring significant value to Fulcrum in his new role.”
About Bryan Stuart
Bryan Stuart joined Fulcrum as COO in 2018. Before Fulcrum, he served as president and chief executive officer of Yarra Therapeutics and president and chief executive officer of Kastle Therapeutics, both companies focused on developing therapies for rare diseases. Before Kastle, Bryan was chief business officer of Civitas Therapeutics and previously led business development, corporate development, and strategy at both EKR Therapeutics and Ovation Pharmaceuticals.
“I am honored to become Fulcrum’s next CEO and to lead our exceptional team, especially at such an exciting time for the company,” said Bryan Stuart. “Along with a strong bench of leadership talent and support from the Board, I am confident in our ability to continue to advance our clinical programs, external collaborations, and Product Engine to develop and deliver therapies to people living with rare genetic diseases. We have a lot of important work ahead of us as we expect to report meaningful updates from our clinical programs in FSHD and sickle cell disease later this year.”
Bryan earned his MBA from the Kellogg School at Northwestern University and his bachelor’s degree from the University of Illinois.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene misexpression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.
For more information: https://www.fulcrumtx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
